Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis

Detaylı Bibliyografya
Asıl Yazarlar:	Sørensen, P, Deisenhammer, F, Duda, P, Hohlfeld, R, Myhr, K, Palace, J, Polman, C, Pozzilli, C, Ross, C
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	Wiley-Blackwell 2010

Benzer Materyaller

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.
Yazar:: Sørensen, P, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

THE INFLUENCE OF NEUTRALIZING ANTIBODIES TO INTERFERON-BETA ON PROGRESSION OF MULTIPLE SCLEROSIS
Yazar:: V. Yu. Lizhdvoy, ve diğerleri
Baskı/Yayın Bilgisi: (2016-07-01)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis.
Yazar:: Delphine Bachelet, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta.
Yazar:: Sonia Gavasso, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Beta-interferons in multiple sclerosis
Yazar:: Aggarwal Sourabh, ve diğerleri
Baskı/Yayın Bilgisi: (2010-01-01)

Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
Yazar:: Lampasona, V, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

beta-interferon treatment does not immediately slow the progression of axonal injury in multiple sclerosis
Yazar:: Parry, A, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
Yazar:: Parry, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Interferon beta treatment of multiple sclerosis.
Yazar:: Markovitz, D
Baskı/Yayın Bilgisi: (1994)

PHARMACOGENETICS OF INTERFERON BETA IN MULTIPLE SCLEROSIS
Yazar:: Mohamed Rayen Ganouni, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
Yazar:: Cefaro Luca, ve diğerleri
Baskı/Yayın Bilgisi: (2009-10-01)

Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
Yazar:: Barletta Valeria, ve diğerleri
Baskı/Yayın Bilgisi: (2011-02-01)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
Yazar:: Jenny Link, ve diğerleri
Baskı/Yayın Bilgisi: (2017-01-01)

INTERFERON-BETA TREATMENT OF MULTIPLE-SCLEROSIS - REPLY
Yazar:: Sibley, W, ve diğerleri
Baskı/Yayın Bilgisi: (1994)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis.
Yazar:: Clerico, M, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis.
Yazar:: Sarah Burkill, ve diğerleri
Baskı/Yayın Bilgisi: (2019-01-01)

MOTOR SKILL LEARNING IN MULTIPLE SCLEROSIS
Yazar:: Tomassini, V, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Review: Neutralizing antibodies against interferon-beta
Yazar:: Per Soelberg Sorensen
Baskı/Yayın Bilgisi: (2008-09-01)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
Yazar:: Filippini, G, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Treatment of multiple sclerosis with interferon beta-1 b.
Yazar:: Abdul-Ahad, A, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis.
Yazar:: Jenny Link, ve diğerleri
Baskı/Yayın Bilgisi: (2014-01-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
Yazar:: Petkau, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
Yazar:: Mahe J, ve diğerleri
Baskı/Yayın Bilgisi: (2013-08-01)

Functional correlates of motor learning in multiple sclerosis
Yazar:: Tomassini, V, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients.
Yazar:: Lisa G M van Baarsen, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Sarcoidosis and multiple sclerosis: systemic toxicity associated with the use of interferon-beta therapy
Yazar:: C. Carbonelli, ve diğerleri
Baskı/Yayın Bilgisi: (2015-12-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Yazar:: Petkau, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Treatment of multiple sclerosis with interferon beta-1b - Reply
Yazar:: Sibley, W, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

A cost-utility analysis of interferon beta for multiple sclerosis.
Yazar:: Parkin, ve diğerleri
Baskı/Yayın Bilgisi: (1998-01-01)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
Yazar:: Masoud Mohammad Malekzadeh, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

The multiple sclerosis PRISMS study: Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis
Yazar:: Ebers, G, ve diğerleri
Baskı/Yayın Bilgisi: (1997)

Reversible Pulmonary Arterial Hypertension Associated with Interferon-Beta Treatment for Multiple Sclerosis
Yazar:: E Gibbons, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Relating brain damage to brain plasticity in patients with multiple sclerosis.
Yazar:: Tomassini, V, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Designing of an ELISA Method for the Measurement of Serum Antibodies against Interferon-beta and the Study of the Frequency of these Antibodies in Patients with Multiple Sclerosis Treated with CinnoVex
Yazar:: Nasrin Zare, ve diğerleri
Baskı/Yayın Bilgisi: (2012-11-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
Yazar:: Damiano Paolicelli, ve diğerleri
Baskı/Yayın Bilgisi: (2016-01-01)

Preservation of motor skill learning in patients with multiple sclerosis
Yazar:: Tomassini, V, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Preservation of motor skill learning in patients with multiple sclerosis.
Yazar:: Tomassini, V, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Yazar:: Ebers, G, ve diğerleri
Baskı/Yayın Bilgisi: (1998)

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
Yazar:: Duquette, P, ve diğerleri
Baskı/Yayın Bilgisi: (1996)